

Philip Gribbon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1271253/publications.pdf>

Version: 2024-02-01

64
papers

2,207
citations

257357

24
h-index

243529

44
g-index

69
all docs

69
docs citations

69
times ranked

3425
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. Briefings in Bioinformatics, 2022, 23, .	3.2	7
2	The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Reports, 2022, 17, 307-320.	2.3	138
3	Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 1049.	1.8	13
4	Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain. Drugs, 2022, 82, 357-373.	4.9	11
5	Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities. ACS Pharmacology and Translational Science, 2022, 5, 226-239.	2.5	43
6	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. Scientific Data, 2022, 9, .	2.4	17
7	An automated and high-throughput-screening compatible pluripotent stem cell-based test platform for developmental and reproductive toxicity assessment of small molecule compounds. Cell Biology and Toxicology, 2021, 37, 229-243.	2.4	6
8	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Scientific Data, 2021, 8, 70.	2.4	65
9	A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. ACS Pharmacology and Translational Science, 2021, 4, 1079-1095.	2.5	44
10	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. ACS Pharmacology and Translational Science, 2021, 4, 1096-1110.	2.5	101
11	X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science, 2021, 372, 642-646.	6.0	240
12	Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. Life, 2021, 11, 810.	1.1	9
13	Droplet-based vitrification of adherent human induced pluripotent stem cells on alginate microcarrier influenced by adhesion time and matrix elasticity. Cryobiology, 2021, 103, 57-69.	0.3	4
14	Discovery pipelines for marine resources: an ocean of opportunity for biotechnology?. World Journal of Microbiology and Biotechnology, 2019, 35, 107.	1.7	10
15	Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology, 2019, 26, 1295-1305.e6.	2.5	10
16	Identification and Characterization of Approved Drugs and Drug-Like Compounds as Covalent Escherichia coli ClpP Inhibitors. International Journal of Molecular Sciences, 2019, 20, 2686.	1.8	5
17	High-Throughput Fluorescence Polarization Assay to Identify Ligands Using Purified G Protein-Coupled Receptor. SLAS Discovery, 2019, 24, 915-927.	1.4	12
18	±-Amino Diphenyl Phosphonates as Novel Inhibitors of Escherichia coli ClpP Protease. Journal of Medicinal Chemistry, 2019, 62, 774-797.	2.9	23

#	ARTICLE	IF	CITATIONS
19	EU-OPENSREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. <i>SLAS Discovery</i> , 2019, 24, 398-413.	1.4	12
20	The European Marine Biological Research Infrastructure Cluster: An Alliance of European Research Infrastructures to Promote the Blue Bioeconomy. <i>Grand Challenges in Biology and Biotechnology</i> , 2018, , 405-421.	2.4	5
21	<i>In vitro</i> and <i>in silico</i> analysis of the effects of D_2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations. <i>British Journal of Pharmacology</i> , 2018, 175, 4121-4136.	2.7	14
22	Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERB β . <i>Journal of Biological Methods</i> , 2018, 5, e94.	1.0	10
23	A Label-Free Continuous Fluorescence-Based Assay for Monitoring Ornithine Decarboxylase Activity with a Synthetic Putrescine Receptor. <i>SLAS Discovery</i> , 2017, 22, 906-914.	1.4	23
24	Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience. <i>Stem Cell Research</i> , 2017, 20, 105-114.	0.3	51
25	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 1129-1135.	2.6	20
26	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit <i>Trypanosoma brucei</i> Pteridine Reductase in Support of Early-Stage Drug Discovery. <i>ACS Omega</i> , 2017, 2, 5666-5683.	1.6	24
27	A high-content small molecule screen identifies novel inducers of definitive endoderm. <i>Molecular Metabolism</i> , 2017, 6, 640-650.	3.0	32
28	The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor. <i>Frontiers in Pharmacology</i> , 2017, 8, 667.	1.6	31
29	Establishing the Secondary Metabolite Profile of the Marine Fungus: <i>Tolyposcladium geodes</i> sp. MF458 and Subsequent Optimisation of Bioactive Secondary Metabolite Production. <i>Marine Drugs</i> , 2017, 15, 84.	2.2	27
30	Biophysical characterization of <i>E. coli</i> TolC interaction with the known blocker hexaamminecobalt. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2702-2709.	1.1	21
31	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7598-7616.	2.9	41
32	Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase. <i>Journal of Biomolecular Screening</i> , 2016, 21, 689-694.	2.6	13
33	Risk mitigation in academic drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 333-336.	2.5	5
34	Towards a hit for every target. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 1-2.	21.5	27
35	Stem cell reprogramming: Basic implications and future perspective for movement disorders. <i>Movement Disorders</i> , 2015, 30, 301-312.	2.2	5
36	A Phenotypic Screening Approach to Identify Anticancer Compounds Derived from Marine Fungi. <i>Assay and Drug Development Technologies</i> , 2014, 12, 162-175.	0.6	9

#	ARTICLE	IF	CITATIONS
37	Development of a Colorimetric and a Fluorescence Phosphatase-Inhibitor Assay Suitable for Drug Discovery Approaches. <i>Journal of Biomolecular Screening</i> , 2013, 18, 899-909.	2.6	18
38	Development of an Assay for Complex I/Complex III of the Respiratory Chain Using Solid Supported Membranes and Its Application in Mitochondrial Toxicity Screening in Drug Discovery. <i>Assay and Drug Development Technologies</i> , 2011, 9, 147-156.	0.6	2
39	A Bioluminogenic HDAC Activity Assay: Validation and Screening. <i>Journal of Biomolecular Screening</i> , 2011, 16, 1227-1235.	2.6	37
40	Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 681-690.	2.5	21
41	Induced pluripotent stem cells: a new tool for toxicology screening?. <i>Archives of Toxicology</i> , 2009, 83, 641-644.	1.9	25
42	High-throughput hit finding and compound-profiling technologies for academic drug discovery. <i>Drug Discovery Today: Technologies</i> , 2008, 5, e3-e7.	4.0	4
43	Hyaluronan Binding to Link Module of TSG-6 and to G1 Domain of Aggrecan Is Differently Regulated by pH. <i>Journal of Biological Chemistry</i> , 2008, 283, 32294-32301.	1.6	28
44	Feasibility study using surface-enhanced Raman spectroscopy for the quantitative detection of tyrosine and serine phosphorylation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007, 1770, 912-918.	1.1	30
45	Analysing the Output from Primary Screening. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2006, 9, 331-337.	0.6	4
46	The Application of Fluorescence Lifetime Readouts in High-Throughput Screening. <i>Journal of Biomolecular Screening</i> , 2006, 11, 765-772.	2.6	20
47	A Novel Method for Analyzing [Ca ²⁺] Flux Kinetics in High-Throughput Screening. <i>Journal of Biomolecular Screening</i> , 2006, 11, 511-518.	2.6	7
48	High-throughput drug discovery: What can we expect from HTS?. <i>Drug Discovery Today</i> , 2005, 10, 17-22.	3.2	162
49	NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening. <i>Journal of Biomolecular Screening</i> , 2005, 10, 573-580.	2.6	21
50	Evaluating Real-Life High-Throughput Screening Data. <i>Journal of Biomolecular Screening</i> , 2005, 10, 99-107.	2.6	73
51	Experiences in Implementing uHTS - Cutting Edge Technology Meets the Real World. <i>Current Drug Discovery Technologies</i> , 2004, 1, 27-35.	0.6	12
52	Fluorescence readouts in HTS: no gain without pain?. <i>Drug Discovery Today</i> , 2003, 8, 1035-1043.	3.2	122
53	Measuring Intracellular Calcium Fluxes in High Throughput Mode. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2003, 6, 355-362.	0.6	53
54	Development of a 1- μ l Scale Assay for Mitogen-Activated Kinase Kinase 7 Using 2-D Fluorescence Intensity Distribution Analysis Anisotropy. <i>Journal of Biomolecular Screening</i> , 2002, 7, 419-428.	2.6	14

#	ARTICLE	IF	CITATIONS
55	THE APPLICATION OF CONFOCAL MICROSCOPY TO THE STUDY OF LIPOSOME ADSORPTION ONTO BACTERIAL BIOFILMS. <i>Journal of Liposome Research</i> , 2002, 12, 285-300.	1.5	44
56	Novel Confocal-FRAP Analysis of Carbohydrate-Protein Interactions Within the Extracellular Matrix. , 2001, 171, 487-494.		3
57	Confocal-FRAP Analysis of ECM Molecular Interactions. , 2000, 139, 83-93.		3
58	The analysis of intermolecular interactions in concentrated hyaluronan solutions suggest no evidence for chain-chain association. <i>Biochemical Journal</i> , 2000, 350 Pt 1, 329-35.	1.7	20
59	The Molecular Basis of the Solution Properties of Hyaluronan Investigated by Confocal Fluorescence Recovery After Photobleaching. <i>Biophysical Journal</i> , 1999, 77, 2210-2216.	0.2	104
60	New approaches to the investigation of hyaluronan networks. <i>Biochemical Society Transactions</i> , 1999, 27, 124-127.	1.6	8
61	Macromolecular Diffusion of Biological Polymers Measured by Confocal Fluorescence Recovery after Photobleaching. <i>Biophysical Journal</i> , 1998, 75, 1032-1039.	0.2	126
62	Alpha-1-acid (AAG, orosomuroid) glycoprotein: interaction with bacterial lipopolysaccharide and protection from sepsis. <i>Inflammation</i> , 1997, 21, 69-82.	1.7	61
63	Time dependent effects of trypsin treatment of human red cells. <i>Clinical Hemorheology and Microcirculation</i> , 1993, 13, 473-479.	0.9	1
64	Electronic laboratory notebooks in a publicâ€“private partnership. <i>PeerJ Computer Science</i> , 0, 2, e83.	2.7	2